On December 31, 2018 Pfizer Inc. reported that it invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 8:30 a.m. Pacific Standard Time (Press release, Pfizer, DEC 31, 2018, View Source [SID1234532320]). Effective January 1, 2019, Albert Bourla will become Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today.

On December 31, 2018 Enzychem Lifesciences, a leading global biopharmaceutical company focusing on innovative new drug development for unmet medical needs, reported that it will present at Biotech Showcase 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square (Press release, Enzychem Lifesciences, DEC 31, 2018, View Source [SID1234532326]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO & Chairman, Mr. Ki Young Sohn will present at Biotech Showcase as follows:

Date: Tuesday, January 8, 2019
Time: 9:30 am PT
Room: Franciscan A (Ballroom Level)
Location: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

On December 28, 2019 Helix BioPharma Corp. (TSX, FSE: "HBP") ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, reported it has closed a final tranche of a private placement financing for gross proceeds of CAD348,000 (Press release, Helix BioPharma, DEC 28, 2018, View Source [SID1234533055]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The terms of the placement are for the purchase of units at $1.20 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

ACM Alpha Consulting Management AG provided financial advisory services to Helix in connection with the private placement.

On December 28, 2018 Medtronic plc (NYSE:MDT), the global leader in medical technology, reported it will participate in the 37th Annual J.P. Morgan Healthcare Conference in San Francisco (Press release, Medtronic, DEC 28, 2018, View Source;p=RssLanding&cat=news&id=2381699 [SID1234532302]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Omar Ishrak, Medtronic chairman and chief executive officer, will make a formal presentation on the company beginning at 9:00 a.m. PST (11:00 a.m. CST) on Monday, January 7, 2019. Shortly following the presentation, Ishrak and Karen Parkhill, executive vice president and chief financial officer, will answer questions on the company.

A live audio webcast of the presentation and Q&A session will be available on January 7, 2019, by clicking on the Investor Events link at View Source An archive of the presentation and Q&A session will be available on the same webpage later in the day.

On December 28, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported that management will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference onMonday, January 7, 2019 at 10:30 am PT (1:30 pm ET) at The Westin St. Francis in San Francisco (Press release, Alnylam, DEC 28, 2018, View Source;p=RssLanding&cat=news&id=2381687 [SID1234532303]). This presentation will include an update on unaudited fourth quarter 2018 global net product revenues for ONPATTRO (patisiran) as well as additional updates on the product’s commercial launch. In addition, the Company will webcast the Q&A breakout session immediately following its presentation at 11:00 am PT (2:00 pm ET).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of both the presentation and breakout session will be available on the Investors section of the Company’s website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after the event.